AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22153280 — intervention group
Group type: COMPARATOR
Intervention: Repeat epidural
Number of subjects: 97
Study 22153280 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia and Repeat epidural
Number of subjects: 97
Study 19915480 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg + Haloperidol 1.5 mg
Number of subjects: 160
Study 19915480 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg + Placebo
Number of subjects: 160
Study 17975386 — intervention group
Group type: EXPERIMENTAL
Intervention: Early renal replacement therapy
Number of subjects: 0
Study 17975386 — intervention group
Group type: COMPARATOR
Intervention: Standard timing of renal replacement therapy
Number of subjects: 0
Study 16249547 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 1 mg/day for 12 months (group B1)
Number of subjects: 58
Study 16249547 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B2)
Number of subjects: 58
Study 11844826 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorozole (2.5 mg per day for 12 weeks)
Number of subjects: 100
Study 11844826 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg per day for 12 weeks)
Number of subjects: 100
Study 11844826 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study 10091968 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (one-hour session)
Number of subjects: 42
Study 10091968 — intervention group
Group type: COMPARATOR
Intervention: Written information about the risks related to drinking during pregnancy
Number of subjects: 42
Study 7789450 — intervention group
Group type: COMPARATOR
Intervention: Unopposed flexions of about 55‐70 degrees (control trials)
Number of subjects: 0
Study 7789450 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements opposed by spring‐like loads generated by a torque motor
Number of subjects: 0
Study 7789450 — intervention group
Group type: EXPERIMENTAL
Intervention: Movements opposed by high loads (80‐90% of maximal voluntary contraction)
Number of subjects: 0
Study 7789450 — intervention group
Group type: EXPERIMENTAL
Intervention: High load conditions
Number of subjects: 0
Study 2104074 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (500 mg t.d.s.)
Number of subjects: 206
Study 2104074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study 373646 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate delivered as an aerosol
Number of subjects: 14
Study 373646 — intervention group
Group type: COMPARATOR
Intervention: Beclomethasone dipropionate delivered as a powder from a rotahaler
Number of subjects: 14
Study 30295512 — intervention group
Group type: EXPERIMENTAL
Intervention: Residual pseudo-likelihood estimator using GLIMMIX procedure of SAS
Number of subjects: 0
Study 30295512 — intervention group
Group type: COMPARATOR
Intervention: Method of moments
Number of subjects: 0
Study 30295512 — intervention group
Group type: COMPARATOR
Intervention: Analysis of variance estimators
Number of subjects: 0
Study 29061068 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-layer PR technique using peritoneum
Number of subjects: 48
Study 29061068 — intervention group
Group type: COMPARATOR
Intervention: Standard PR technique
Number of subjects: 48
Study 26209422 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced reciprocating gait orthosis with thoracolumbosacral orthosis
Number of subjects: 4
Study 26209422 — intervention group
Group type: COMPARATOR
Intervention: Advanced reciprocating gait orthosis without thoracolumbosacral orthosis
Number of subjects: 4
Study 24398053 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg once daily at bedtime
Number of subjects: 150
Study 24398053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 22672145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03% DSC127
Number of subjects: 172
Study 22672145 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% DSC127
Number of subjects: 172
Study 22672145 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study 19463030 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational music therapy
Number of subjects: 105
Study 19463030 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control
Number of subjects: 105
Study 17126472 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal tracheal combitube (ETC)
Number of subjects: 20
Study 17126472 — intervention group
Group type: COMPARATOR
Intervention: Tracheal intubation (TI)
Number of subjects: 20
Study 15023156 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg/day
Number of subjects: 493
Study 15023156 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg/day
Number of subjects: 493
Study 15023156 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (both doses)
Number of subjects: 493
Study 11117910 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem (rate control)
Number of subjects: 252
Study 11117910 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (rhythm control)
Number of subjects: 252
Study 9179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Likert-type format
Number of subjects: 0
Study 9179323 — intervention group
Group type: COMPARATOR
Intervention: Garfield format
Number of subjects: 0
Study 9179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Above average students with Garfield format
Number of subjects: 0
Study 9179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Average students with Garfield format
Number of subjects: 0
Study 9179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Average students with Likert-type format
Number of subjects: 0
Study 9179323 — intervention group
Group type: EXPERIMENTAL
Intervention: Below average students with Likert-type format
Number of subjects: 0
Study 8212823 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose given to 34 children with anti-HBs titres lower or slightly higher than 100 IU l‐1
Number of subjects: 79
Study 8212823 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial vaccination against hepatitis B
Number of subjects: 79
Study 3082179 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron-beam irradiation (25-30 Gy boost)
Number of subjects: 115
Study 3082179 — intervention group
Group type: COMPARATOR
Intervention: Photon-beam irradiation (25-30 Gy boost)
Number of subjects: 115
Study 3082179 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutron-beam irradiation
Number of subjects: 115
Study 3082179 — intervention group
Group type: COMPARATOR
Intervention: Photon-beam irradiation
Number of subjects: 115
Study 31861951 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium alginate
Number of subjects: 72
Study 31861951 — intervention group
Group type: COMPARATOR
Intervention: Thickened formula
Number of subjects: 72
Study 28275307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrotalcite combined with esomeprazole
Number of subjects: 48
Study 28275307 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole alone
Number of subjects: 48
Study 26674505 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitinol closure clip
Number of subjects: 46
Study 26674505 — intervention group
Group type: COMPARATOR
Intervention: RMAF procedure
Number of subjects: 46
Study 23364004 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (10 μg vitamin D(3)/d and 1.2 g Ca/d, with 375 μg weekly)
Number of subjects: 82
Study 23364004 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent to 63 μg (2500 IU)/d and 10 μg (400 IU)/d)
Number of subjects: 82
Study 23364004 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (WL)
Number of subjects: 82
Study 23364004 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance (WM)
Number of subjects: 82
Study 21487114 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-uncertainty manipulation
Number of subjects: 0
Study 21487114 — intervention group
Group type: EXPERIMENTAL
Intervention: Thinking about a self-expressive possession
Number of subjects: 0
Study 17584993 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 17584993 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 400 mg
Number of subjects: 0
Study 16734552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.4 IU/kg)
Number of subjects: 71
Study 16734552 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 71
Study 16734552 — intervention group
Group type: COMPARATOR
Intervention: Insulin ultralente
Number of subjects: 71
Study 16734552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (0.3 IU/kg)
Number of subjects: 71
Study 16734552 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (tailor-made dose)
Number of subjects: 71
Study 12617377 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisensory stimulation (MSE)
Number of subjects: 12
Study 12617377 — intervention group
Group type: COMPARATOR
Intervention: Relaxation activities (control group)
Number of subjects: 12
Study 10833675 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training (10-week, group-based cognitive-behavioral stress management intervention)
Number of subjects: 30
Study 10833675 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation training
Number of subjects: 30
Study 9165640 — intervention group
Group type: EXPERIMENTAL
Intervention: Pay ($3.40/hr)
Number of subjects: 150
Study 9165640 — intervention group
Group type: COMPARATOR
Intervention: No-Pay
Number of subjects: 150
Study 7903572 — intervention group
Group type: EXPERIMENTAL
Intervention: Arnica Montana
Number of subjects: 0
Study 7903572 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or no treatment)
Number of subjects: 0
Study 2423408 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylase inhibitor
Number of subjects: 4
Study 2423408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study 31050930 — intervention group
Group type: EXPERIMENTAL
Intervention: Photon Lase III (100 mW, 4 J/cm2‐1 J/cm2 each point, 10 sec per point with wavelength of 808 nm)
Number of subjects: 60
Study 30487757 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal binding (AB)
Number of subjects: 20
Study 30487757 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 20
Study 28255259 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block and sciatic nerve block (PCS)
Number of subjects: 60
Study 28255259 — intervention group
Group type: COMPARATOR
Intervention: Unilateral spinal anaesthesia (USA)
Number of subjects: 60
Study 24333515 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging/transrectal ultrasound fusion guided biopsy
Number of subjects: 105
Study 24367568 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple group
Number of subjects: 36
Study 24367568 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex group
Number of subjects: 36
Study 24367568 — intervention group
Group type: COMPARATOR
Intervention: Random group
Number of subjects: 36
Study 20545217 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0015% tafluprost ophthalmic solution
Number of subjects: 94
Study 20545217 — intervention group
Group type: COMPARATOR
Intervention: Placebo ophthalmic solution
Number of subjects: 94
Study 19085497 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis during total hip arthroplasty (exact intervention details not provided)
Number of subjects: 188
Study 19085497 — intervention group
Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis during total hip arthroplasty
Number of subjects: 188
Study 16619567 — intervention group
Group type: EXPERIMENTAL
Intervention: PS76A2 (15 ng mistletoe lectin/0.5 ml)
Number of subjects: 352
Study 16619567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 352
Study 16619567 — intervention group
Group type: EXPERIMENTAL
Intervention: PS76A2
Number of subjects: 352
Study 12746765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole plus placebo (800 mg per day)
Number of subjects: 219
Study 12746765 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole plus amphotericin B (0.7 mg/kg per day for the first 5-6 days)
Number of subjects: 219
Study 10810947 — intervention group
Group type: EXPERIMENTAL
Intervention: Printed educational materials designed to encourage patients to quit smoking, eat less fat, and increase physical activity.
Number of subjects: 915
Study 10810947 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician advice to quit smoking, eat less fat, or get more exercise prior to receiving intervention materials.
Number of subjects: 915
Study 7531023 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical therapy (ECT) with systemic chemotherapy
Number of subjects: 26
Study 7531023 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical therapy (ECT) alone
Number of subjects: 26
Study 7531023 — intervention group
Group type: COMPARATOR
Intervention: Control group (systemic chemotherapy alone)
Number of subjects: 26
Study 3279010 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg orally four times a day for 2 weeks)
Number of subjects: 11
Study 3279010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 3279010 — intervention group
Group type: COMPARATOR
Intervention: Running-in period
Number of subjects: 11
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score at positive end‐expiratory pressure 5
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score at positive end‐expiratory pressure 5
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Each step increase of regional Lung Ultrasound score
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score and CT classification at positive end‐expiratory pressure 5
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional Lung Ultrasound score and CT classification at positive end‐expiratory pressure 15
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Lung Ultrasound score at positive end‐expiratory pressure 15
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Not aerated tissue at positive end‐expiratory pressure 15
Number of subjects: 20
Study 30048331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung Ultrasound score variations
Number of subjects: 20
Study 28388937 — intervention group
Group type: EXPERIMENTAL
Intervention: Experience-based co-design intervention
Number of subjects: 0
Study 28388937 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 27707450 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga
Number of subjects: 186
Study 27707450 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Number of subjects: 186
Study 27707450 — intervention group
Group type: COMPARATOR
Intervention: Usual Activity
Number of subjects: 186
Study 23649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with mild hepatic impairment
Number of subjects: 26
Study 23649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with moderate hepatic impairment
Number of subjects: 26
Study 23649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam 100 mg single oral dose in participants with severe hepatic impairment
Number of subjects: 26
Study 23649964 — intervention group
Group type: COMPARATOR
Intervention: Brivaracetam 100 mg single oral dose in healthy controls
Number of subjects: 26
Study 23649964 — intervention group
Group type: COMPARATOR
Intervention: Comparison of brivaracetam disposition in hepatic impairment versus healthy controls
Number of subjects: 26
Study 23649964 — intervention group
Group type: EXPERIMENTAL
Intervention: Brivaracetam metabolism in hepatic impairment
Number of subjects: 26
Study 22191234 — intervention group
Group type: EXPERIMENTAL
Intervention: Phototherapeutic treatment in addition to standard radio- and hormonal therapy (n=308)
Number of subjects: 559
Study 22191234 — intervention group
Group type: COMPARATOR
Intervention: Standard radio- and hormonal therapy alone (n=251)
Number of subjects: 559
Study 22191234 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival in the study group (localized and generalized tumors)
Number of subjects: 559
Study 19088057 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading
Number of subjects: 68
Study 19088057 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric loading plus shock-wave treatment
Number of subjects: 68
Study 17452150 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d of pioglitazone
Number of subjects: 28
Study 17452150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pioglitazone)
Number of subjects: 28
Study 15284252 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan treatment continued until disease progression (n = 25)
Number of subjects: 333
Study 15284252 — intervention group
Group type: COMPARATOR
Intervention: Irinotecan treatment stopped after 8 cycles (n = 30)
Number of subjects: 333
Study 11506437 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day continuous wear
Number of subjects: 504
Study 11506437 — intervention group
Group type: COMPARATOR
Intervention: 7-day extended wear
Number of subjects: 504
Study 9754822 — intervention group
Group type: EXPERIMENTAL
Intervention: Linomide 2.5 mg
Number of subjects: 63
Study 9754822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 7872447 — intervention group
Group type: EXPERIMENTAL
Intervention: Nopikex soap (20% diethyl toluamide and 0.5% permethrin)
Number of subjects: 0
Study 7872447 — intervention group
Group type: COMPARATOR
Intervention: Placebo soap
Number of subjects: 0
Study 7872447 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 2191485 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thrombolytic therapy (rt-PA)
Number of subjects: 0
Study 2191485 — intervention group
Group type: COMPARATOR
Intervention: Intravenous thrombolytic therapy (streptokinase)
Number of subjects: 0
Study 2191485 — intervention group
Group type: COMPARATOR
Intervention: Early intervention with PTCA or surgery
Number of subjects: 0
Study 679080 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic cephaloridine perioperatively
Number of subjects: 0
Study 679080 — intervention group
Group type: COMPARATOR
Intervention: Oral neomycin and erythromycin base preoperatively
Number of subjects: 0
Study 31842026 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram 1 mg/kg ideal body weight
Number of subjects: 100
Study 31842026 — intervention group
Group type: COMPARATOR
Intervention: Control group (no doxapram)
Number of subjects: 100
Study 30019629 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 1091
Study 30019629 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 1091
Study 30019629 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke mimics
Number of subjects: 1091
Study 28829992 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX
Number of subjects: 267
Study 28829992 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil-cisplatin
Number of subjects: 267
Study 26414847 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-Assisted Laparoscopic Donor Nephrectomy (RDN)
Number of subjects: 45
Study 26414847 — intervention group
Group type: COMPARATOR
Intervention: Standard Laparoscopic Donor Nephrectomy (LDN)
Number of subjects: 45
Study 23644928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium selenite at 750 microg/24 h for 6 days
Number of subjects: 72
Study 23644928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21710401 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-Generation Antipsychotics (SGAs)
Number of subjects: 278
Study 21710401 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and trial-related barriers
Number of subjects: 278
Study 21710401 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug company representatives as information source
Number of subjects: 278
Study 19704100 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD treatment
Number of subjects: 0
Study 19704100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16001181 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/day plus calcium 1,000 mg/day and vitamin D 800 IU/day
Number of subjects: 316
Study 16001181 — intervention group
Group type: COMPARATOR
Intervention: Control (alfacalcidol 1 mug/day plus calcium 500 mg/day or vitamin D 1,000 IU/day plus calcium 800 mg/day)
Number of subjects: 316
Study 15167985 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrating platform device (10 min/day for 6 months)
Number of subjects: 24
Study 15167985 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (10 min/day for 6 months)
Number of subjects: 24
Study 11746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP), repeated three times at 1-week intervals.
Number of subjects: 22
Study 11746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) in responder subgroup.
Number of subjects: 22
Study 11746532 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration leukocytapheresis (LCP) in both subgroups.
Number of subjects: 22
Study 11746532 — intervention group
Group type: COMPARATOR
Intervention: Control group (sham apheresis), n=7.
Number of subjects: 22
Study 9423948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 26) using the new retrograde cardioplegia cannula with a long balloon (3 cm)
Number of subjects: 52
Study 9423948 — intervention group
Group type: COMPARATOR
Intervention: Group II (n = 26) using a standard cannula (balloon length 8 mm)
Number of subjects: 52
Study 9423948 — intervention group
Group type: EXPERIMENTAL
Intervention: Group I (n = 26)
Number of subjects: 52